Abstract:AIM: To construct the recombinant lentivirus expression plasmid, pLenti6/V5-NT4p53(N15)-antennapedia (Ant), and study its effect on HepG2 cells.METHODS: Plasmid pLenti6/V5-NT4p53(N15)-Ant was constructed incorporating the following functional regions, including signal peptide sequence and pro-region of neurotrophin 4, N-terminal residues 12-26 of p53 and 17 amino acid drosophila carrier protein, Ant. Hepatocellular carcinoma (HepG2) cells were used for transfection. 3-[4,5-dimethyl-thiazol-2yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, lactate dehydrogenase (LDH) release assay, transmission electron microscopy (TEM) and flow cytometric analysis (FCM) were employed to investigate the effects of LV-NT4(Si)p53(N15)-Ant in vitro on HepG2 cells. In vivo experiment was also performed to investigate the inhibitory effect of LV-NT4(Si)-p53(N15)-Ant on tumor growth in nude mice.RESULTS: LV-NT4(Si)-p53(N15) -Ant significantly suppressed the growth of HepG2 cells. MTT assay showed that the growth of HepG2 cells was mucj more significantly inhibited by LV-NT4(Si)-p53(N15)-Ant than by LV-EGFP. The inhibition rate for HepG2 cell growth in the two groups was 46.9% and 94.5%, respectively, 48 h after infection with LV-NT4(Si)-p53(N15)-Ant, and was 33.9% and 95.8%, respectively, 72 h after infection with LV-NT4(Si)-p53(N15)-Ant (P < 0.01). Light microscopy and TEM showed morphological changes in HepG2 cells infected with LV-NT4(Si)-p53(N15)-Ant, but no significant changes in HepG2 cells infected with LV-EGFP. Changes were observed in ultra-structure of HepG2 cells infected with LV-NT4(Si)-p53(N15)-Ant, with degraded membranes, resulting in necrosis. LDH release from HepG2 cells was analyzed at 24, 48, 72 and 96 h after infection with LV-NT4(Si)-p53(N15)-Ant and LV-EGFP, which showed that LDH release was significantly higher in LV-NT4(Si)-p53(N15)-Ant treatment group (682 IU/L) than in control group (45 IU/L, P < 0.01). The longer the time was after infection, the bigger the difference was in LDH release. FCM analysis showed that LV-NT4(Si)p53(N15)-Ant could induce two different kinds of cell death: necrosis and apoptosis, with apoptosis being the minor type and necrosis being the main type, suggesting that LV-NT4(Si)-p53(N15)-Ant exerts its anticancer effect on HepG2 cells by inducing necrosis. The in vivo study showed that LV-NT4(Si)-p53(N15)-Ant significantly inhibited tumor growth with an inhibition rate of 66.14% in terms of tumor size and weight.CONCLUSION: LV-NT4(Si)-p53(N15)-Ant is a novel recombinant lentivirus expression plasmid and can be used in gene therapy for cancer. (C) 2009 The WJG Press and Baishideng. All rights reserved.

Secretory expression of p53(N15)-Ant following lentivirus-mediated gene transfer induces cell death in human cancer cells.

Nt4(Si)-P53(N15)-Antennapedia Induces Cell Death in A Human Hepatocellular Carcinoma Cell Line

Recombinant Lentivirus-Mediated Gene Transfer of NT4-p53 (N15 ) -Ant Inhibits the Growth of Hepatocellular Carcinoma Cells in Vitro

[Construction and Antitumor Effect of Recombinant Adenovirus Vector Containing Heterofusion Gene NT4p53(N15)Ant].

Construction and Identification of Recombinant Adenovirus Vector Harboring Fusion Gene NT4-p53 (N15)-Ant

Anti-tumor Effects of P53n15-Based Fusion Peptide in the Transfected H1299 Lung Cancer Cells

Construction and Identification of Recombinant Adeno-Associated Virus Vector Mediating the Expression of the Derepressing P73 Peptide-P53 (N37)

Development of P53 Protein Transduction Therapy Using Membrane-Permeable Peptides and the Application to Oral Cancer Cells.

Recombinant Newcastle Disease Virus Expressing P53 Demonstrates Promising Antitumor Efficiency in Hepatoma Model.

Anti-tumor Efficacy of P53 with 9R Cell-Penetrating Peptides

Recombinant Adeno-Associated Virus Expressing a P53-Derived Apoptotic Peptide (37AA) Inhibits HCC Cells Growth in Vitro and in Vivo

A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers.

Therapeutic effects of recombinant adenovirus expressing fusion peptide NT4p53(N15)Ant on mice bearing transplanted liver cancer

In Vitro Investigation of Recombinant Adenovirus-p53 Reversing the Resistance of Non-Small Cell Lung Cancer to Cisplatin

Construction of Recombinant Adenovirus Harboring Fusion Gene NT4p53(C22)Ant and Its Killing Effect on HepG2 Tumor Cells

N-Isopropylacrylamide-modified Polyethylenimine-Mediated P53 Gene Delivery to Prevent the Proliferation of Cancer Cells

A Universal Gene Carrier Platform for Treatment of Human Prostatic Carcinoma by P53 Transfection

Anticancer Activity of Oncolytic Adenoviruses Carrying P53 is Augmented by 11R in Gallbladder Cancer Cell Lines in Vitro and in Vivo

Expression and Immunogenicity Analysis of p53 Protein Fused with a New Cell-Penetrating Peptide

Inhibition of Cell Proliferation and Migration Through Nucleobase-Modified Polyamidoamine-Mediated P53 Delivery

[Adenovirus-Mediated Killing of Hepatocellular Carcinoma HepG2 Cells by Heterogeneous Fusion Gene NT4p53(N15)Ant].